The stock of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) is a huge mover today! The stock decreased 5.83% or $0.35 during the last trading session, reaching $5.65. About 555,305 shares traded. Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) has declined 94.14% since December 4, 2018 and is downtrending. It has underperformed by 94.14% the S&P500.
The move comes after 8 months negative chart setup for the $19.51 million company. It was reported on Dec, 4 by Barchart.com. We have $5.48 PT which if reached, will make NASDAQ:HEPA worth $585,420 less.
More notable recent Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) news were published by: Nasdaq.com which released: “BUZZ-U.S. STOCKS ON THE MOVE-Netflix, J&J, Hepion Pharma, Coca-Cola – Nasdaq” on October 18, 2019, also Nasdaq.com with their article: “Boeing 777X fuselage split during Sept stress test – Nasdaq” published on November 27, 2019, Nasdaq.com published: “Goldman Sachs: 3 â€œStrong Buyâ€ Stocks to Snap Up Now – Nasdaq” on November 26, 2019. More interesting news about Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) were released by: Benzinga.com and their article: “52 Biggest Movers From Friday – Benzinga” published on December 02, 2019 as well as Nasdaq.com‘s news article titled: “BUZZ-U.S. STOCKS ON THE MOVE-EyeGate, Danaos, Uber, Nordstrom – Nasdaq” with publication date: November 22, 2019.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. The company has market cap of $19.51 million. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. It currently has negative earnings. The firm was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.